Skip to main content
Home
Latest news
Browse topics
Lupus Rheumatoid arthritis Spondyloarthropathies COVID-19 Browse all topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA Anifrolumab for the treatment of SLE JAK inhibitor safety: Weighing up the data and understanding the risks Rituximab and rheumatology practice in the COVID-19 era Safety snapshot: Upadacitinib in patients with PsA Repurposing rheumatology drugs for COVID-19 Telemedicine in rheumatology: COVID-19 and beyond Managing PsA in resource-limited settings
Conferences
ACR Convergence 2022 EULAR 2022 Congress
About us
Medicine Matters Rheumatology
EXTENDED SEARCH
10 search results for:

Voclosporin 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-08-2022 | Lupus nephritis | News | Article
    approvalsWatch

    Voclosporin set for EMA approval for lupus nephritis

    The EMA recommends that voclosporin should be used in combination with mycophenolate mofetil for treating active class III, IV, or V lupus nephritis in adults.

    Author:
    Claire Barnard
  2. 10-11-2021 | ACR 2021 | Conference coverage | Article
    News in brief

    ​​​​​​​AURORA 2 shows enduring proteinuria benefits with voclosporin in lupus nephritis

    Voclosporin has a sustained proteinuria-reducing effect in patients with lupus nephritis, suggests an interim analysis of the AURORA 2 study.

    Author:
    Lucy Piper
    Published in:
    ACR Convergence 2021; 3–9 November
  3. 18-05-2021 | Lupus nephritis | News | Article

    AURORA 1: Voclosporin improves renal outcomes in patients with lupus nephritis

    Adding the calcineurin inhibitor voclosporin to background immunosuppressive therapy improves renal response rates among people with lupus nephritis, show phase 3 trial results published in The Lancet .

    Author:
    Claire Barnard
    Published in:
    Lancet 2021; doi:10.1016/S0140-6736(21)00578-X Lancet 2021; doi:10.1016/S0140-6736(21)00663-2
  4. 08-11-2021 | ACR 2021 | Conference coverage | Article

    Add-on treatment for lupus nephritis: Should belimumab or voclosporin be used first?

    “This has been a controversial point for belimumab efficacy,” unlike in the voclosporin trial, in which the between-group difference for voclosporin versus placebo did reach statistical significance in the 45 Black patients, Petri conceded.

    Author:
    Claire Barnard
    Published in:
    ACR Convergence 2021; 3–9 November
  5. 02-02-2021 | Lupus nephritis | News | Article
    approvalsWatch

    Voclosporin approved for lupus nephritis in the USA

    medwireNews : The US FDA has approved voclosporin, a calcineurin inhibitor, as the first oral treatment option for active lupus nephritis.

    Author:
    Claire Barnard
  6. 24-05-2021 | ACR 2021 | Teaser

    ACR Convergence 2021 highlights

    3–9 November: Keep up with the latest news and interviews from the conference.

  7. 10-07-2021 | Adis Journal Club | Article
    Pediatric Drugs

    An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus

    Calcineurin inhibitors (cyclosporine, tacrolimus, voclosporin) appear to be a good option for cSLE patients with lupus nephritis.

  8. 20-06-2019 | Systemic lupus erythematosus | Highlight | Article

    Systemic lupus erythematosus: Novel therapies and targeted treatments

    Glomerular filtration rate decreased with voclosporin.

    Author:
    Andrea Fava, George Stojan
  9. 29-01-2019 | Lupus nephritis | Editorial | Article

    Emerging therapies for lupus nephritis

    The AURA-LV phase II trial (NCT02141672), which compared two dosing regimens of voclosporin to placebo on background steroids and MMF, generated a higher response rate with low dose voclosporin compared with placebo (49.4% vs 23.9% at 48 weeks).

    Author:
    Lara El Khoury, Richard Furie
  10. 20-06-2019 | Systemic lupus erythematosus | Highlight | Teaser
    Expert Opinion: Editorial

    Systemic lupus erythematosus: Novel therapies and targeted treatments

    Andrea Fava and George Stojan review new strategies and agents for the treatment of systemic lupus erythematosus that have most recently showed promise in clinical trials.

  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.